nevirapine and Cardiovascular Diseases studies

Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

Excerpt	Relevance	Reference
"ARTEN is a randomized, open-label, non-inferiority trial that compares nevirapine (NVP) 200 mg twice daily or 400 mg once daily to atazanavir/ritonavir (ATZ/r) 300 mg/100 mg once daily, each combined with fixed-dose tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg once daily, in antiretroviral-naive HIV-1 patients with CD4(+) T-cell counts <400 (men) and <250 cells/mm(3) (women)."	2.76	Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. ( Andrade-Villanueva, J; Antunes, F; Arastéh, K; de Rossi, L; Di Perri, G; Domingo, P; Gellermann, H; Lutz, T; Migrone, H; Opravil, M; Podzamczer, D; Soriano, V; Taylor, S, 2011)
" These data have now provided a clear and clinically relevant understanding of the individual profiles of drugs within the nucleoside analogue reverse transcriptase inhibitor , HIV protease inhibitor and non-nucleoside analogue reverse transcriptase inhibitor drug classes, and have provided a rational basis for assessing and monitoring these adverse effects in clinical practice."	2.43	Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. ( Mallal, S; Nolan, D; Reiss, P, 2005)

Research

Studies (10)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Proportion of Patients Reporting CNS (Central Nervous System) Side Effects of Any Severity

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (10.00)	18.2507
2000's	3 (30.00)	29.6817
2010's	6 (60.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Kiage, JN	1
Heimburger, DC	1
Nyirenda, CK	1
Wellons, MF	1
Bagchi, S	1
Chi, BH	1
Koethe, JR	1
Arnett, DK	1
Kabagambe, EK	1
Shaffer, D	1
Hughes, MD	1
Sawe, F	1
Bao, Y	1
Moses, A	1
Hogg, E	1
Lockman, S	1
Currier, J	1
Parienti, JJ	1
Verdon, R	1
Maggi, P	1
Bellacosa, C	1
Carito, V	1
Perilli, F	1
Lillo, A	1
Volpe, A	1
Trillo, G	1
Angiletta, D	1
Regina, G	1
Angarano, G	1
Soriano, V	1
Arastéh, K	1
Migrone, H	1
Lutz, T	1
Opravil, M	1
Andrade-Villanueva, J	1
Antunes, F	1
Di Perri, G	1
Podzamczer, D	1
Taylor, S	1
Domingo, P	1
Gellermann, H	1
de Rossi, L	1
Nolan, D	2
Reiss, P	1
Mallal, S	1
Buchacz, K	1
Weidle, PJ	1
Moore, D	1
Were, W	1
Mermin, J	1
Downing, R	1
Kigozi, A	1
Borkowf, CB	1
Ndazima, V	1
Brooks, JT	1
Dieleman, JP	1
Hillebrand-Haverkort, ME	1
van der Ende, ME	1
Sturkenboom, MC	1
Lange, JM	1
Stricker, BH	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Randomized, Open Label Study Evaluating the Lipid Profile Difference and Efficacy of a Combined Therapy Including Tenofovir, Emtricitabine + Atazanavir / r or NVP in Naive HIV - 1 Infected Patients.[NCT00389207]	Phase 3	576 participants (Actual)	Interventional	2006-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Proportion of Patients reporting CNS (central nervous system) side effects of any severity (NCT00389207)
Timeframe: week 148

Proportion of Patients Reporting Hepatic Events of Any Severity

Intervention	participants (Number)
Nevirapine QD	41
Nevirapine BID	41
Atazanvir/Ritonavir	37

Proportion of Patients reporting hepatic events of any severity (NCT00389207)
Timeframe: week 148

Proportion of Patients Reporting Rash of Any Severity

Intervention	participants (Number)
Nevirapine QD	26
Nevirapine BID	24
Atazanvir/Ritonavir	92

Proportion of Patients reporting rash of any severity (NCT00389207)
Timeframe: week 148

Time to Loss of Virologic Response (Rebound)

Intervention	participants (Number)
Nevirapine QD	75
Nevirapine BID	64
Atazanvir/Ritonavir	74

Time to loss of virologic response (TLOVR) was defined as the time from start of treatment to the first measurement showing VL ≥ 50 copies/mL in the first virologic rebound, after having a confirmed virological response. (NCT00389207)
Timeframe: Baseline to week 144

Time to Treatment Failure

Intervention	weeks (Median)
Nevirapine QD	143.86
Nevirapine BID	143.21
Nevirapine QD+BID	143.71
Atazanvir/Ritonavir	143.00

Treatment failure is defined as the occurrence of the first of at least one of the following events: early discontinuation of trial drug, change in ARV therapy, failure to achieve an HIV RNA count < 50 copies/mL up to Visit 10 (week 48) or loss of virologic response (NCT00389207)
Timeframe: baseline to week 144

Time to Treatment Response (First Confirmed VL<50 Copies/mL)

Intervention	weeks (Median)
Nevirapine QD	143.86
Nevirapine BID	143.21
Nevirapine QD+BID	143.71
Atazanvir/Ritonavir	143.00

Time to treatment response was defined as the time from start of treatment until the first measurement of the first confirmed virological response (NCT00389207)
Timeframe: baseline to week 144

Change in CD4+ Count From Baseline

Intervention	weeks (Median)
Nevirapine QD	12.00
Nevirapine BID	12.14
Nevirapine QD+BID	12.00
Atazanvir/Ritonavir	23.71

Change in CD4+ cell count from baseline among patients on treatment at each visit, with the final visit at Week 144 or EOT (NCT00389207)
Timeframe: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT

Change in Framingham Score From Baseline

Intervention	cells/mm^3 (Mean)
	Change in CD4+ count to Week 4	Change in CD4+ count to Week 8	Change in CD4+ count to Week 12	Change in CD4+ count to Week 24	Change in CD4+ count to Week 36	Change in CD4+ count to Week 48	Change in CD4+ count to Week 60	Change in CD4+ count to Week 72	Change in CD4+ count to Week 84	Change in CD4+ count to Week 96	Change in CD4+ count to Week 108	Change in CD4+ count to Week 120	Change in CD4+ count to Week 132	Change in CD4+ count to Week 144/EOT
Atazanvir/Ritonavir	86.1	98.0	110.9	133.8	163.4	183.6	208.2	231.9	246.4	251.6	267.2	269.2	281.3	285.8
Nevirapine QD+BID	77.2	105.6	120.3	134.4	160.1	168.2	184.8	213.7	223.0	217.7	231.2	231.3	243.4	251.0

Change in the estimated risk of cardiovascular disease using the Framingham algorithm from baseline to after 48, 96 and 144 weeks, last observation carried forward (LOCF). The score is based on age, gender, systolic blood pressure, total cholesterol, high density lipoprotein cholesterol and smoking status. Scores range from 0 to 21 with higher scores indicating a greater risk. (NCT00389207)
Timeframe: From baseline to Weeks 48, 96 and 144/EOT

Change in Mental Health Summary (MHS) Score From Baseline

Intervention	Units on a scale (Mean)
	Change in Framingham score to Week 48	Change in Framingham score to Week 96	Change in Framingham score to Week 144/EOT
Atazanvir/Ritonavir	0.66	1.19	0.82
Nevirapine QD+BID	0.50	0.93	1.14

Quality of life (QoL) assessment by change in MHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the Medical Outcomes Study HIV Health Survey (MOS-HIV), a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL. The MHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL. (NCT00389207)
Timeframe: From baseline to Weeks 48, 96 and 144/EOT

Change in Physical Health Summary (PHS) Score From Baseline

Intervention	Units on a scale (Mean)
	Change in MHS score to Week 48	Change in MHS score to Week 96	Change in MHS score to Week 144/EOT
Atazanvir/Ritonavir	4.52	4.89	4.70
Nevirapine QD+BID	6.09	6.10	4.76

QoL assessment by change in PHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the MOS-HIV, a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL. The PHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL. (NCT00389207)
Timeframe: From baseline to Weeks 48, 96 and 144/EOT

Change in the Calculated Glomerular Filtration Rate (GFR) at Week 48, 96 and 144

Intervention	Units on a scale (Mean)
	Change in PHS score to Week 48	Change in PHS score to Week 96	Change in PHS score to Week 144/EOT
Atazanvir/Ritonavir	3.35	3.00	3.35
Nevirapine QD+BID	3.34	3.19	2.22

Calculations based on the MDRD algorithm. (NCT00389207)
Timeframe: From baseline to Week 48, 96, 144

Change of Cholesterol Values From Baseline to Week 48, 96, 144

Intervention	mL/min/1.73 m^2 (Mean)
	change baseline to week 48 (N=143, 128, 271, 173)	change baseline to week 96 (N=130, 122, 252, 157)	change baseline to week 144 (N=163, 168, 331, 174)
Atazanvir/Ritonavir	-7.18	-11.53	-9.56
Nevirapine BID	-5.92	-10.02	-6.33
Nevirapine QD	-3.91	-6.93	-3.27
Nevirapine QD+BID	-4.86	-8.42	-4.82

Changes frombaseline in total cholesterol, LDL-cholesterol(LDL-c) and HDL (NCT00389207)
Timeframe: baseline to week 48, 96, 144

Change of hsCRP From Baseline to Week 48, 96, 144

Intervention	mg/dL (Mean)
	total cholesterol, week 48 (N=138,122,164)	total cholesterol, week 96 (N=124,114,147)	total cholesterol, week 144 (N=154,155,160)	LDL-c, week 48 (N=136,117,159)	LDL-c, week 96 (N=119,110,145)	LDL-c, week 144 (N=151,150,157)	HDL, week 48(N=138,122,164)	HDL, week 96 (N=124,114,147)	HDL, week 144(N=154,155,160)
Atazanvir/Ritonavir	20.84	29.99	28.13	10.58	19.19	17.61	3.49	4.74	5.73
Nevirapine BID	29.54	36.87	30.66	17.70	21.66	17.95	11.59	13.33	10.47
Nevirapine QD	29.28	39.17	33.12	16.54	21.93	21.42	12.06	13.86	12.61

Change of hsCRP from baseline to week 48, 96, 144 (NCT00389207)
Timeframe: baseline to week 48, 96, 144

Change of Total Cholesterol to HDL-cholesterol Ratio From Baseline to Week 48, 96, 144

Intervention	mg/L (Mean)
	hsCRP, week 48 (N=142,126,173)	hsCRP, week 96 (N=128,120,157)	hsCRP, week 144 (N=160,164,174)
Atazanvir/Ritonavir	-0.70	0.35	0.04
Nevirapine BID	-0.67	-0.79	-0.02
Nevirapine QD	-1.01	-1.54	-0.09

Change of Total cholesterol to HDL-cholesterol ratio from baseline to week 48, 96, 144 (NCT00389207)
Timeframe: baseline to week 48, 96, 144

Change of Total Triglycerides From Baseline to Week 48, 96, 144

Intervention	ratio (Mean)
	total triglycerides, week 48 (N=138,122,164)	total triglycerides, week 96 (N=124,114,147)	total triglycerides, week 144 (N=154,155,160)
Atazanvir/Ritonavir	0.20	0.28	0.17
Nevirapine BID	-0.33	-0.25	-0.07
Nevirapine QD	-0.37	-0.22	-0.24

Change of total triglycerides from baseline to week 48, 96, 144 (NCT00389207)
Timeframe: baseline to week 48, 96, 144

Changes of Apolipoprotein Values From Baseline to Week 48, 96, 144

Intervention	mg/dL (Mean)
	total triglycerides, week 48 (N=138,120,164)	total triglycerides, week 96 (N=124,113,147)	total triglycerides, week 144 (N=153,153,159)
Atazanvir/Ritonavir	36.28	30.45	27.11
Nevirapine BID	1.67	5.35	6.11
Nevirapine QD	0.08	9.34	-3.46

Changes frombaseline apolipoprotein A1 & B (NCT00389207)
Timeframe: baseline to week 48, 96, 144

Genotypic Resistance Associated With Virologic Failure

Intervention	g/L (Mean)
	apolipoprotein A1, week 48 (N=134,121,156)	apolipoprotein A1, week 96 (N=115,106,141)	apolipoprotein A1, week 144 (N=144,140,148)	apolipoprotein B, week 48 (N=134,120,156)	apolipoprotein B, week 96 (N=115,106,141)	apolipoprotein B, week 144 (N=144,139,148)
Atazanvir/Ritonavir	0.08	0.07	0.06	0.03	0.03	0.03
Nevirapine BID	0.23	0.23	0.14	0.03	-0.00	0.05
Nevirapine QD	0.23	0.23	0.16	0.00	0.00	0.01

Number of treatment-emergent drug-associated substitutions in patients with virological failure up to Week 48. The total number of genotypic mutations in those patients who were virologic failures is given, not the number of patients with mutations. (NCT00389207)
Timeframe: From baseline to Week 48

Glycaemic Abnormalities

Intervention	Number of substitutions (Number)
	Emtricitabine-associated substitutions at Week 48	Tenofovir-associated substitutions at Week 48	Nevirapine-associated substitutions at Week 48
Atazanvir/Ritonavir	0	0	0
Nevirapine QD+BID	21	11	34

Number of patients with AE elevated serum glucose (NCT00389207)
Timeframe: From baseline to Week 144

Lipodystrophy

Intervention	Patients (Number)
	Number with glycaemic abnormalities	Number without glycaemic abnormalities
Atazanvir/Ritonavir	3	190
Nevirapine QD+BID	0	376

Number of patients with AE lipodystrophy (NCT00389207)
Timeframe: From baseline to Week 144

Non-scheduled Physician Visits

Intervention	Patients (Number)
	Number with lipodystrophy	Number without lipodystrophy
Atazanvir/Ritonavir	1	192
Nevirapine QD+BID	1	375

Cost effectiveness assessment by number of patients with non-scheduled physician visits (NCT00389207)
Timeframe: From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT

Number of Patients Hospitalized

Intervention	patients (Number)
	Number between baseline and Week 24	Number between Week 24 and Week 48	Number between Week 48 and Week 96	Number between Week 96 and Wk 144/EOT
Atazanvir/Ritonavir	35	35	28	35
Nevirapine QD+BID	74	45	58	58

Cost effectiveness assessment by number of patients hospitalized (NCT00389207)
Timeframe: From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT

Proportion of Patients With >= DAIDS Grade 2 Laboratory Abnormalities

Proportion of Patients With Virologic Failure at Week 48, 96, 144

Proportion of Patients With Virological Rebound With VL >=400 Copies/mL After CVR at Week 24, 48, 96, 144

Intervention	Patients (Number)
	Number hospitalized between baseline and Week 24	Number hospitalized between Week 24 and Week 48	Number hospitalized between Week 48 and Week 96	Number hospitalized between Week 96 and Wk 144/EOT
Atazanvir/Ritonavir	2	5	5	1
Nevirapine QD+BID	8	6	5	9

Intervention	participants (Number)
	DAIDS 2 moderate	DAIDS 3 severe	DAIDS 4 potential lifethreatening
Atazanvir/Ritonavir	72	39	9
Nevirapine BID	84	28	15
Nevirapine QD	74	30	9

Intervention	participants (Number)
	virologic failure at Week 48	virologic failure at Week 96	virologic failure at Week 144
Atazanvir/Ritonavir	25	13	17
Nevirapine BID	25	25	28
Nevirapine QD	20	15	19
Nevirapine QD+BID	45	40	47

The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL) (NCT00389207)
Timeframe: at Week 24, 48, 96, 144

Proportion of Patients With Virological Rebound With VL >=50 Copies/mL After CVR (Confirmed Virological Response) at Week 24, 48, 96, 144

Intervention	participants (Number)
	virologic rebound after CVR at Week 24	virologic rebound after CVR at Week 48	virologic rebound after CVR at Week 96	virologic rebound after CVR at Week 144
Atazanvir/Ritonavir	2	2	2	5
Nevirapine BID	2	3	6	6
Nevirapine QD	2	3	3	4
Nevirapine QD+BID	4	6	9	10

The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL) (NCT00389207)
Timeframe: at Week 24, 48, 96, 144

Proportion of Patients With VL < 400 Copies/ml

Intervention	participants (Number)
	virologic rebound after CVR at Week 24	virologic rebound after CVR at Week 48	virologic rebound after CVR at Week 96	virologic rebound after CVR at Week 144
Atazanvir/Ritonavir	5	12	10	15
Nevirapine BID	2	5	6	9
Nevirapine QD	3	4	4	8
Nevirapine QD+BID	5	9	10	17

VL <400 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT) (NCT00389207)
Timeframe: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT

Proportion of Patients With VL < 50 Copies/ml

Intervention	Proportion of patients (Number)
	Proportion with VL<400 copies /mL at Week 4	Proportion with VL<400 copies /mL at Week 8	Proportion with VL<400 copies /mL at Week 12	Proportion with VL<400 copies /mL at Week 24	Proportion with VL<400 copies /mL at Week 36	Proportion with VL<400 copies /mL at Week 48	Proportion with VL<400 copies /mL at Week 60	Proportion with VL<400 copies /mL at Week 72	Proportion with VL<400 copies /mL at Week 84	Proportion with VL<400 copies /mL at Week 96	Proportion with VL<400 copies /mL at Week 108	Proportion with VL<400 copies /mL at Week 120	Proportion with VL<400 copies /mL at Week 132	Proportion with VL<400 copies /mL at Week 144/EOT
Atazanvir/Ritonavir	0.287	0.679	0.834	0.956	0.966	0.977	0.988	0.988	0.994	0.987	1.000	0.994	0.993	0.986
Nevirapine QD+BID	0.365	0.714	0.856	0.924	0.968	0.985	0.993	0.996	0.988	1.000	0.996	1.000	0.996	0.991

VL <50 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT) for the patient (NCT00389207)
Timeframe: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT

Serum Lipid Abnormalities

Intervention	Proportion of patients (Number)
	Proportion with VL<50 copies /mL at Week 4	Proportion with VL<50 copies /mL at Week 8	Proportion with VL<50 copies /mL at Week 12	Proportion with VL<50 copies /mL at Week 24	Proportion with VL<50 copies /mL at Week 36	Proportion with VL<50 copies /mL at Week 48	Proportion with VL<50 copies /mL at Week 60	Proportion with VL<50 copies /mL at Week 72	Proportion with VL<50 copies /mL at Week 84	Proportion with VL<50 copies /mL at Week 96	Proportion with VL<50 copies /mL at Week 108	Proportion with VL<50 copies /mL at Week 120	Proportion with VL<50 copies /mL at Week 132	Proportion with VL<50 copies /mL at Week 144/EOT
Atazanvir/Ritonavir	0.09	0.25	0.412	0.779	0.83	0.886	0.901	0.915	0.896	0.924	0.968	0.955	0.947	0.929
Nevirapine QD+BID	0.107	0.304	0.515	0.842	0.907	0.931	0.959	0.965	0.972	0.98	0.964	0.976	0.971	0.952

Number of patients with AE elevated serum lipids (i.e. hypercholesterolaemia) (NCT00389207)
Timeframe: From baseline to Week 144

Treatment Response at Week 144

Intervention	patients (Number)
	Number with serum lipid abnormalities	Number without serum lipid abnormalities
Atazanvir/Ritonavir	4	189
Nevirapine QD+BID	9	367

Treatment response is defined as a viral load (VL) <50 copies/mL measured at two consecutive visits prior to Week 144 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 144. (NCT00389207)
Timeframe: From baseline to Week 144

Treatment Response at Week 48

Intervention	participants (Number)
	Number of responders	Number of non-responders
Atazanvir/Ritonavir	143	50
Nevirapine BID	113	75
Nevirapine QD	121	67
Nevirapine QD+BID	234	142

Treatment response is defined as a viral load (VL) <50 copies/mL measured at two consecutive visits prior to Week 48 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 48. (NCT00389207)
Timeframe: From baseline to Week 48

Treatment Response at Week 48 (TLOVR Algorithm)

Intervention	Patients (Number)
	Number of responders	Number of non-responders
Atazanvir/Ritonavir	126	67
Nevirapine BID	124	64
Nevirapine QD	126	62
Nevirapine QD+BID	250	126

Treatment response is defined as a VL <50 copies/mL measured at two consecutive visits up to Week 48 and without subsequent rebound or change of ARV therapy up to Week 48, based on time to loss of virologic response (TLOVR) algorithm, as a sensitivity analysis for the primary analysis. (NCT00389207)
Timeframe: From baseline to Week 48

Treatment Response at Week 96

Intervention	Patients (Number)
	Number of responders	Number of non-responders
Atazanvir/Ritonavir	142	51
Nevirapine QD+BID	261	115

Treatment response is defined as a viral load (VL) <50 copies/mL measured at two consecutive visits prior to Week 96 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 96. (NCT00389207)
Timeframe: From baseline to Week 96

Treatment-emergent AIDS-defining Illness

Intervention	participants (Number)
	Number of responders	Number of non-responders
Atazanvir/Ritonavir	149	44
Nevirapine BID	122	66
Nevirapine QD	131	57
Nevirapine QD+BID	253	123

Treatment-emergent AIDS-defining illness (tr.-emerg. AIDS-def.illness) including worsening during treatment (NCT00389207)
Timeframe: From baseline to Week 144

Treatment-emergent AIDS-defining Illness Leading to Death

Intervention	Patients (Number)
	Number with tr.-emerg. AIDS-def.illness	Number without tr.-emerg. AIDS-def.illness
Atazanvir/Ritonavir	7	186
Nevirapine QD+BID	26	350

Patients with an AIDS-defining illness leading to death broken out by treatment. Statistical analysis shows time to death from AIDS-defining illness. (NCT00389207)
Timeframe: From baseline to Week 144

Article	Year
[Nevirapine and cardiovascular risk]. Medecine et maladies infectieuses, 2010, Volume: 40, Issue:9 Topics: Anti-HIV Agents; Cardiovascular Diseases; Humans; Nevirapine; Risk Factors	2010
Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert opinion on drug safety, 2005, Volume: 4, Issue:2 Topics: Adenine; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardi	2005
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy? Drug safety, 2005, Volume: 28, Issue:12 Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Cardiovascular Diseases; Cyclopropanes; HIV Infection	2005

Article	Year
Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE). Journal of acquired immune deficiency syndromes (1999), 2014, Jun-01, Volume: 66, Issue:2 Topics: Adenine; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active;	2014
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antiviral therapy, 2011, Volume: 16, Issue:3 Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cardiovascular Diseases; Deoxycytidine; Emtrici	2011

Article	Year
Cardiometabolic risk factors among HIV patients on antiretroviral therapy. Lipids in health and disease, 2013, Apr-10, Volume: 12 Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxa	2013
Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens. The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:4 Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Blood Chemical Analysis; Blood Glucose; Cardiov	2011
[Goal: a long-term successful HIV therapy. Nevirapine as sustained-release tablet offers good prospects]. MMW Fortschritte der Medizin, 2012, May-16, Volume: 154 Suppl 1 Topics: Anti-HIV Agents; Cardiovascular Diseases; Delayed-Action Preparations; Dose-Response Relationship, D	2012
Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. Journal of acquired immune deficiency syndromes (1999), 2008, Mar-01, Volume: 47, Issue:3 Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly	2008
[Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors]. Nederlands tijdschrift voor geneeskunde, 1998, Dec-26, Volume: 142, Issue:52 Topics: Adult; Cardiovascular Diseases; CD4 Lymphocyte Count; Diabetes Mellitus, Type 2; Drug Therapy, Combi	1998

Intervention	Patients (Number)
	Number with AIDS-def. illness leading to death	Number without AIDS-def. illness leading to death
Atazanvir/Ritonavir	0	193
Nevirapine QD+BID	3	373

nevirapine and Cardiovascular Diseases